NEW YORK (GenomeWeb News) – Waters today said that revenues in the third quarter dropped about 1 percent year over year as foreign currency translation tamped down sales by 3 percent.

For the three months ended Sept. 29, Waters reeled in $450.0 million in total revenue, down from $454.5 million a year ago and short of consensus Wall Street estimates of $451.1 million.

According to Chairman, President, and CEO Douglas Berthiaume, Waters saw stable pharmaceutical demand as well as strong sales in Asia allowing the company to grow organically during the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.